All In Biotech

Drug Trial Radar · NCT03722576

Vidofludimus Calcium for Primary Sclerosing Cholangitis

Investigation of the Activity of Vidofludimus Calcium, a Novel, Orally Available, Small Molecule Inhibitor of Dihydroorotate Dehydrogenase, as a Treatment for Primary Sclerosing Cholangitis (PSC)

Last checked: Nov 19, 2026Latest source record: Oct 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

18

Actual

Start

Jun 17, 2019

Primary completion

Jun 30, 2020

Study completion Jun 30, 2020

Sponsor

Lead sponsor
Elizabeth CareyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Arizona State University
First posted
Oct 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To examine the safety, tolerability, and efficacy of daily dosing with vidofludimus calcium over a 6-month period.

Conditions

  • Primary Sclerosing Cholangitis

Interventions

  • Vidofludimus calciumDrug

    During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjects Who Experience a Positive Outcome as Measured by Combination of Serum Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST) Levels.Time frame: Baseline to 24 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Phoenix, Arizona

  • Arizona State University

    Tempe, Arizona

  • Mayo Clinic in Rochester

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.